Daiichi Sankyo is a global research-driven pharmaceutical company headquartered in Tokyo, Japan. The company discovers, develops, manufactures, and markets prescription medicines, with operations spanning the Americas, Europe, and Asia.
Its core focus is oncology—particularly antibody-drug conjugates (ADCs) built on its DXd payload and linker platform—alongside cardiovascular and other therapeutic areas. Daiichi Sankyo maintains integrated R&D and GMP manufacturing capabilities covering small molecules, biologics, conjugation, and sterile fill‑finish, supported by quality, regulatory, and supply chain functions. The company collaborates with industry partners on targeted cancer therapies and supplies medicines worldwide. For the chemical and life sciences sector, Daiichi Sankyo is notable for its expertise in complex API synthesis, biologics production, and ADC process development, which combine medicinal chemistry, bioconjugation, and advanced manufacturing to deliver targeted therapeutics.
None yet. When a new project in the record names Daiichi Sankyo as owner, partner or investor, it shows here.
BLA for I‑DXd seeking accelerated approval in extensive‑stage SCLC withdrawn after FDA said Phase 2 data were insufficient; Phase 3 programmes continue.
BLA for ifinatamab deruxtecan accepted and granted FDA Priority Review for adult ES‑SCLC post‑platinum therapy; PDUFA Oct 10, 2026. Based on IDeate‑Lung01 Phase 2 (B7‑H3 DXd ADC).
Raludotatug deruxtecan achieved a 50.5% response rate in phase 2 for platinum-resistant ovarian cancer, with a 5.6 mg/kg dose selected for phase 3.
Ifinatamab deruxtecan achieved a 48.2% response rate in ES-SCLC patients, with ongoing regulatory discussions and consistent safety profile.
The Pfaffenhofen site will develop cancer therapies, create 350 jobs by 2030, and enhance ADC technology. The expansion includes new labs, renewable energy use, and collaboration with local partners.
